Articol

Workshop sheds light on important statistical advances for the biopharma industry

  • Lin Li

  • Lira Pi

Statistical advancements to solve important questions surrounding drug development and regulatory science were explored in depth during the recent ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW). The workshop, held in Rockville, Maryland from 24 to 26 September 2025, attracted 1,000+ statistician professionals from industry and regulatory agencies as well as academia.1

General impression

Statistical science is being leveraged more frequently during interdisciplinary collaboration, including the use of AI/ML that informs data-driven decision-making in the biopharmaceutical industry.

  • The FDA paper “Artificial Intelligence & Medical Products” exemplifies how the different centers at the US Food and Drug Administration (FDA) work together to explore the development and use of AI across the medical product life cycle.2
  • The theme of the RISW conference, “Future in Statistics: Collaboration and Innovation in the AI/ML Era”, is an indicator of the new trend of integrating statistics with AI. That has been echoed at other prominent conferences such as the 2025 Joint Statistical Meetings, themed “statistics, data science, and AI enriching society”3, and is expected to be top of mind at the 2026 ENAR Biometrics Meeting with the theme of “The role of statistics in an AI-augmented world."4

RISW key takeaways

Statistics and AI/ML have empowered modern clinical trials to rigorously leverage external information to obtain clinical evidence that can be used for regulatory decisions. Randomized clinical trials could be made more efficient with Bayesian adaptive designs. This could result in a higher statistical power with the same sample size or, assuming the same power, a smaller expected sample size or shorter expected duration. 

Borrowing information from external controls, such as natural history or real-world data (RWD), could potentially reduce the need for large control groups, especially in rare diseases or when a placebo arm presents ethical concerns. Proper statistical approaches make single-arm trial design possible and feasible. In addition, statistical frameworks combining machine learning and causal inference can learn from external information while addressing confounding and bias properly. Such approaches have shown promise in clinical trials to estimate treatment effect in a principled, data-adaptive way. As a result, a smaller trial is possible given the same statistical power.
Another important focus area during the workshop was patient enrichment strategies for clinical trials. Discussions focused on the potential these strategies have for increasing the efficiency of drug development and supporting precision medicine. 

Often such strategies are centered around assessing heterogeneous treatment effect and identifying patients more likely to benefit from specific treatments (e.g., treatment-responsive subgroups). The potential outcome framework, a core concept in causal inference, is increasingly integrated into causal ML to discover patterns in clinical trial data and identify patient subgroups. In the context of biomarkers, this could lead to co-development of companion diagnostics and important statistical and design considerations in studies such as bridging studies.

Workshop conclusions

The workshop raised important considerations about statistical advancements, supported by AI/ML, to address many of the questions and challenges clinical trials and drug development face. By leveraging statistical advancements, biopharmaceutical companies can apply broader and deeper insights to the design and conduct of clinical trials and to more efficient drug development.

About the authors:

Lin Li is Head of Clinical Statistics and Computational Biology at Cencora. He provides data-driven and tailored solutions that integrate biostatistics, bioinformatics, computer science, and biology to tackle challenges in discovery and clinical development. 

Lira Pi is Associate Director, Statistics at Cencora. She is a statistical methodologist who leads the development and application of novel statistical approaches, such as AI/ML and Bayesian methods, throughout both non-clinical and clinical stages of research.


Disclaimer:
The information provided in this article does not constitute legal advice. Cencora, Inc., strongly encourages readers to review available information related to the topics discussed and to rely on their own experience and expertise in making decisions related thereto.
 


Luați legătura cu echipa noastră

Echipa noastră de experți în valoare este dedicată transformării dovezilor, informațiilor privind politicile și informațiilor de piață în strategii eficiente de acces la piața globală. Permiteți-ne să vă ajutăm să navigați cu încredere prin peisajul complex al asistenței medicale din ziua de azi. Contactați-ne pentru a afla în ce mod vă putem sprijini în atingerea obiectivelor.

Sources


1. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. https://www.amstat.org/meetings/asa-biopharmaceutical-section-regulatory-industry-statistics-workshop
2. Artificial intelligence and medical products: How CBER, CDER, CDRH and OCP are working together, FDA. OMP CDER AI Discussion Paper
3. Joint Statistical Meetings 2025, Nashville, TN, 2-7 August 2025. https://ww2.amstat.org/meetings/jsm/2025/index.cfm
4. ENAR 2026 Spring Meeting, March 15-18, Indianapolis, IN. ENAR 2026 Spring Meeting: Meetings - ENAR <cfoutput>2026</cfoutput> Spring Meeting

 

Resurse conexe

Webinar

Mai multe detalii

Articol

RAPS Convergence 2025: Transparency, Trust, and Resilience in Regulatory Science
Mai multe detalii

Articol

The complex path to meeting promotional materials requirements in Europe
Mai multe detalii

Cencora.com furnizează traduceri automate pentru a ajuta la citirea site-ului web în alte limbi decât engleza. În aceste traduceri, s-au depus eforturi rezonabile pentru a oferi o calitate corectă. Cu toate acestea, nicio traducere automată nu este perfectă și nici nu este destinată să înlocuiască traducătorii umani. Aceste traduceri sunt furnizate ca serviciu utilizatorilor site-ului Cencora.com și sunt furnizate „ca atare”. Nu se oferă nicio garanție de niciun fel, expresă sau implicită, cu privire la acuratețea, fiabilitatea sau corectitudinea oricăreia dintre aceste traduceri efectuate din limba engleză în orice altă limbă. Este posibil ca unele conținuturi (cum ar fi imagini, videoclipuri, Flash etc.) să nu fie traduse cu acuratețe din cauza limitărilor software-ului de traducere.

Orice discrepanțe sau diferențe create în traducerea acestui conținut din limba engleză într-o altă limbă nu au caracter contractual și nu au niciun efect juridic privind conformitatea, aplicarea sau orice alt scop. Dacă sunt identificate erori, vă rugăm să ne contactați . Dacă apar întrebări legate de acuratețea informațiilor conținute în aceste traduceri, vă rugăm să consultați versiunea în limba engleză a paginii.